Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/E ratio is N/A as of 2026-10-02T20:20:55.004Z.
Calculation as of: 2026-10-02T20:20:55.004Z.
Quote observation: 2026-10-02T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: cfe467dbfbd77c451c9134e6671c17e93f9075fb3089474378ac41e20d4454d7
PE RATIO
N/A
| NAME | MARKET CAP | PE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Intellia Therapeutics, Inc. (NTLA) | $1.71B | N/A | N/A | N/A | N/A |
| DENTSPLY SIRONA Inc. (XRAY)vs › | $1.74B | N/A | 23.72 | 50.63 | 57.39 |
| Recursion Pharmaceuticals, Inc. (RXRX)vs › | $2.16B | N/A | N/A | N/A | N/A |
| Teladoc Health, Inc. (TDOC)vs › | $1.00B | N/A | N/A | N/A | N/A |
| Beam Therapeutics Inc. (BEAM)vs › | $2.52B | N/A | N/A | N/A | N/A |
| TransMedics Group, Inc. (TMDX)vs › | $2.76B | 20.67 | 34.18 | 472.96 | 472.96 |
| NeoGenomics, Inc. (NEO)vs › | $474.59M | N/A | 138.05 | 184.03 | 168.06 |
| NRC Health (NRC)vs › | $458.62M | 80.63 | 41.08 | 28.16 | 28.99 |
| Shoulder Innovations, Inc. (SI)vs › | $394.23M | N/A | N/A | N/A | N/A |
| PDS Biotechnology Corporation (PDSB)vs › | $41.86M | N/A | N/A | N/A | N/A |
Trailing P/E
N/A
Forward P/E
N/A
Forward P/E is calculated using analyst consensus EPS estimates for the current or next fiscal year.
Calculation:
Current Price
$12.26
Forward EPS (Est.)
$-3.21
Forward P/E
N/A
Source: FMP Analyst Consensus Estimates. Forward EPS represents the average analyst estimate for the nearest fiscal year.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
